AAV9 Gene Therapy Using a Novel Engineered MIS to Treat Ovarian Cancer
Abstract
Ovarian cancer tumors are heterogeneous, with the bulk of the cells responding well to chemotherapeutics, but a minority of stem-like cells surviving treatment, ultimately leading to recurrence. However, this cancer stem cell is inhibited by Mullerian Inhibiting Substance (MIS). We have begun to evaluate a modified version of recombinant MIS, which we engineered to have greater potency, as well as an alternative delivery mechanism, such as viral gene therapy, in preclinical trials. Furthermore, we are testing MIS on cancer cells isolated from ascites as a way to gauge response rate in the patient population and screen for potential biomarkers.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Aug 07, 2017
- Source ID
- W81XWH1710212
Entities
People
- David Pépin
Organizations
- Massachusetts General Hospital
- United States Army